The will neutralize the biological activity of recombinant human MCP-1.This does not exhibit cross-reactivity with recombinant human RANTES, recombinant human MIP-1á, or recombinant mouse MIP-1á..
Note: Not all species have been tested for usefulness with this product. Only those species listed have been tested. We cannot make any guarantees about additional reactivities which may or may not occur.
Recombinant human MCP-1 (rhMCP-1), expressed in E. coli.
Localization:
Secreted
Species Reactivity:
Cross-reacts with Human.Not yet tested in other species.
Applications:
Uses:
Neut: Use at a concentration of 0.1 ug/ml. Human MCP1 is tested for its ability to neutralize the chemoattractant activity of rhMCP1 for human monocytes. The ND50 of the antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of rhMCP1 that was present at a concentration just high enough to elicit a maximum response. In this bioassay, rhMCP1 was preincubated with various dilutions of the antibody for 1 hour at 37
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Products are guaranteed for 6 months from date of receipt, except for peptides and proteins which are guaranteed for 3 months.
This chemotactic factor attracts monocytes and basophils but not neutrophils or eosinophils and augments monocyte anti-tumor activity. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. It may be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis.